Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.

Authors

Paolo Antonio Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
Bernard Fox, Providence Cancer Center, Portland, OR, United States
Walter Urba, Providence Cancer Center, Portland, OR, United States
Ana Carrizosa Anderson, Department of Neurology, Harvard Medical School, Boston, MA, United States
Michael B Atkins, Oncology Georgetown University, Washington, DC, United States
Ernest C Borden, Comprehensive Cancer Center, University of Wisconsin System, Madison, WI, United States
Julie Brahmer, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
Lisa H Butterfield, Research Parker Institute for Cancer Immunotherapy, San Francisco, CA, United States; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, United States
Alessandra Cesano, ESSA Pharma Inc, Redwood City, CA, United States
Daniel Chen, IGM Biosciences Inc, Mountain View, CA, United States
Tanja de Gruijl, Medical Oncology - Cancer Center Amsterdam, Amsterdam UMC, Locatie VUMC, Amsterdam, Netherlands
Robert O Dillman, AIVITA Biomedical Inc, Irvine, CA, United States
Charles G Drake, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, United States
Leisha A Emens, Medicine, UPMC Hillman Cancer Center, Pittsburgh, United States
Thomas F Gajewski, Pathology and Medicine, University of Chicago, Chicago, IL, United States
James L Gulley, NCI, National Institutes of Health, Bethesda, MD, United States
F Stephen Hodi, Dana Farber Cancer Institute, Boston, MA, United States
Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX, United States
David Kaufman, Bill and Melinda Gates Medical Research Institute, Cambridge, MA, United States
Howard Kaufman, Surgery Immuneering Corp New York, New York, NY, United States
Michael Lotze, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
Douglas G McNeel, Medicine University of Wisconsin Madison, Madison, WI, United States
Kim Margolin, Medical Oncology, City of Hope National Medical Center, Duarte, CA, United States
Francesco Marincola, Refuge Biotechnologies, Menlo Park, CA, United States
Michael J Mastrangelo, Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, PA, United StatesFollow
Marcela V Maus, Massachusetts General Hospital Cancer Center, Harvard Medical Schoo, Massachusetts General Hospital, Boston, MA, United States
David R Parkinson, ESSA Pharma Inc, Palo Alto, CA, United States
Pedro J Romero, Oncology University of Lausanne, Epalinges, VD, Switzerland
Paul M Sondel, Pediatrics University of Wisconsin Madison, Madison, WI, United States
Stefani Spranger, Massachusetts Institute of Technology Koch, Institute for Integrative Cancer Research, Cambridge, MA, United States
Mario Sznol, Yale Cancer Center, Yale School of Medicine, New Haven, CT, United States
George J Weiner, Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA, United States; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, United States; Department of Internal Medicine, Division of General Medicine, University of Iowa, Iowa City, IA, United States
Jon M Wiggington, MacroGenics Inc, Rockville, MD, United States
Jeffrey S Weber, Laura and Isaac Perlmutter Comprehensive Cancer Center, NYU Langone Medical Center, New York, NY, United States

Document Type

Article

Publication Date

4-16-2020

Comments

This article has been peer reviewed. It was published in: Journal for ImmunoTherapy of Cancer.

Volume 8, Issue 1, 16 April 2020 (original published article metadata).

The published (corrected) version is available at DOI: 10.1136/jitc-2020-000878corr1 (Published online 2020 Apr 28)

Copyright © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Recommended Citation

Ascierto, Paolo Antonio; Fox, Bernard; Urba, Walter; Anderson, Ana Carrizosa; Atkins, Michael B; Borden, Ernest C; Brahmer, Julie; Butterfield, Lisa H; Cesano, Alessandra; Chen, Daniel; de Gruijl, Tanja; Dillman, Robert O; Drake, Charles G; Emens, Leisha A; Gajewski, Thomas F; Gulley, James L; Stephen Hodi, F; Hwu, Patrick; Kaufman, David; Kaufman, Howard; Lotze, Michael; McNeel, Douglas G; Margolin, Kim; Marincola, Francesco; Mastrangelo, Michael J; Maus, Marcela V; Parkinson, David R; Romero, Pedro J; Sondel, Paul M; Spranger, Stefani; Sznol, Mario; Weiner, George J; Wiggington, Jon M; and Weber, Jeffrey S, "Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19." (2020). Department of Microbiology and Immunology Faculty Papers. Paper 117.
https://jdc.jefferson.edu/mifp/117

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

PubMed ID

32300051